ECSP14013263A - Inhibidores de la enzima activadora de nedd8 - Google Patents

Inhibidores de la enzima activadora de nedd8

Info

Publication number
ECSP14013263A
ECSP14013263A ECSP14013263A ECSP14013263A EC SP14013263 A ECSP14013263 A EC SP14013263A EC SP14013263 A ECSP14013263 A EC SP14013263A EC SP14013263 A ECSP14013263 A EC SP14013263A
Authority
EC
Ecuador
Prior art keywords
inhibitors
activating enzyme
nedd8 activating
chemical entities
nedd8
Prior art date
Application number
Other languages
English (en)
Inventor
Todd B Sells
Ashley Sue Mccarron
Matthew Stirling
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP14013263A publication Critical patent/ECSP14013263A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen entidades químicas que son inhibidores de la enzima activadora de Nedd8 (NAE), a saber, el compuesto sulfamato de {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-cloro-2 metoxi-2,3-dihidro-1H-inden-1-il]amino}pirimidin-4-il) oxi]-2-hidroxiciclopentil}metilo y sales farmacéuticamente aceptables del mismo; formas en estado sólido del mismo; y profármacos del mismo. También se describen métodos para usar las entidades químicas para tratar trastornos tales como cáncer.
ECSP14013263 2011-08-24 2014-03-21 Inhibidores de la enzima activadora de nedd8 ECSP14013263A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
ECSP14013263A true ECSP14013263A (es) 2014-04-30

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013263 ECSP14013263A (es) 2011-08-24 2014-03-21 Inhibidores de la enzima activadora de nedd8

Country Status (29)

Country Link
US (3) US8809356B2 (es)
EP (2) EP2748168A4 (es)
JP (1) JP6038150B2 (es)
KR (1) KR20140054288A (es)
CN (1) CN103889988B (es)
AR (1) AR087672A1 (es)
AU (1) AU2012298813B2 (es)
BR (1) BR112014004239A2 (es)
CA (1) CA2846231C (es)
CL (1) CL2014000441A1 (es)
CO (1) CO6900148A2 (es)
CR (1) CR20140128A (es)
DO (1) DOP2014000037A (es)
EA (1) EA031067B1 (es)
EC (1) ECSP14013263A (es)
GE (1) GEP201606522B (es)
HK (1) HK1199252A1 (es)
IL (1) IL231069B (es)
MA (1) MA35439B1 (es)
MX (1) MX2014002015A (es)
MY (1) MY166889A (es)
PE (1) PE20141146A1 (es)
PH (1) PH12014500419A1 (es)
SG (2) SG11201400102WA (es)
TN (1) TN2014000080A1 (es)
TW (1) TWI577667B (es)
UA (1) UA114894C2 (es)
UY (1) UY34292A (es)
WO (1) WO2013028832A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MX2014002015A (es) * 2011-08-24 2014-03-27 Millennium Pharm Inc Inhibidores de la enzima activadora de nedd8.
EP3173413B1 (en) 2012-02-17 2019-05-01 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
BR112015032902A8 (pt) * 2013-07-02 2019-12-24 Millennium Pharm Inc compostos de heteroarila, seus usos e composições farmacêuticas
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
EP3901159A1 (en) * 2014-07-01 2021-10-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
KR101927375B1 (ko) * 2016-04-20 2018-12-11 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
PL3792260T3 (pl) 2018-05-08 2024-12-02 Nippon Shinyaku Co., Ltd. Związki azabenzimidazolowe i środki farmaceutyczne
WO2021095801A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 アザベンゾイミダゾール化合物及び医薬
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
WO2004043955A1 (en) 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ユビキチンリガーゼ阻害剤
AU2006210422B2 (en) 2005-02-04 2012-09-13 Takeda Pharmaceutical Company Limited Inhibitors of E1 activating enzymes
CN106008512B (zh) 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
HRP20110017T1 (hr) * 2006-08-08 2011-02-28 Millennium Pharmaceuticals Spojevi heteroarila korisni kao inhibitori e1 aktivirajućih enzima
SG10201402148SA (en) * 2009-05-14 2014-07-30 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MX2014002015A (es) * 2011-08-24 2014-03-27 Millennium Pharm Inc Inhibidores de la enzima activadora de nedd8.
JP6231988B2 (ja) * 2011-11-03 2017-11-15 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Nedd8活性化酵素阻害剤および低メチル化剤の投与

Also Published As

Publication number Publication date
US20130150388A1 (en) 2013-06-13
DOP2014000037A (es) 2014-04-15
KR20140054288A (ko) 2014-05-08
IL231069A0 (en) 2014-03-31
EA031067B1 (ru) 2018-11-30
HK1199252A1 (en) 2015-06-26
JP2014524476A (ja) 2014-09-22
EP2748168A4 (en) 2015-04-22
EP2748168A2 (en) 2014-07-02
SG11201400102WA (en) 2014-03-28
US20150011572A1 (en) 2015-01-08
US20180290983A1 (en) 2018-10-11
MX2014002015A (es) 2014-03-27
TW201313689A (zh) 2013-04-01
CR20140128A (es) 2014-05-15
EA201400249A1 (ru) 2014-05-30
IL231069B (en) 2018-02-28
CL2014000441A1 (es) 2014-09-26
TWI577667B (zh) 2017-04-11
CN103889988B (zh) 2018-05-04
US9850214B2 (en) 2017-12-26
AR087672A1 (es) 2014-04-09
MA35439B1 (fr) 2014-09-01
TN2014000080A1 (en) 2015-07-01
UA114894C2 (uk) 2017-08-28
EP3323414A1 (en) 2018-05-23
BR112014004239A2 (pt) 2017-03-21
PH12014500419A1 (en) 2020-06-22
CA2846231A1 (en) 2013-02-28
AU2012298813B2 (en) 2016-07-28
SG10201601023UA (en) 2016-03-30
NZ622220A (en) 2016-04-29
JP6038150B2 (ja) 2016-12-07
WO2013028832A3 (en) 2013-05-02
US8809356B2 (en) 2014-08-19
AU2012298813A1 (en) 2013-05-02
WO2013028832A2 (en) 2013-02-28
CN103889988A (zh) 2014-06-25
CO6900148A2 (es) 2014-03-20
UY34292A (es) 2013-04-05
PE20141146A1 (es) 2014-09-21
GEP201606522B (en) 2016-08-10
CA2846231C (en) 2017-06-20
MY166889A (en) 2018-07-24

Similar Documents

Publication Publication Date Title
ECSP14013263A (es) Inhibidores de la enzima activadora de nedd8
MX2019006299A (es) Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
GT201500051A (es) Inhibidores de glucosilceramida sintasa
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
MX387487B (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton.
TR201816379T4 (tr) DNA-PK inhibitörleri.
BR112015000399A2 (pt) derivados de pirazolil pirimidina
MX2016004030A (es) Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune.
CR20130550A (es) Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina
CU24265B1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer
PY1212975A (es) Compuestos de azabiclo o quinuclidin-carbamato como inhibidores de glucosilceramida sintasa
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
MX2014015287A (es) Derivado del ester del acido heteroarilcarboxilico.
PE20160113A1 (es) Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2
BR112015006874A2 (pt) ligantes de rig-i inovadores e métodos para produzir os mesmos
CU20160183A7 (es) Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
CR20140553A (es) Compuestos de fenoxietil piperidina
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
DOP2013000304A (es) Moduladores alostéricos positivos del receptor de acetilcolina nicotínico
CR20130583A (es) Moduladores alostéricos positivos del receptor de acetilcolina nicotínico
BR112014012595A2 (pt) processo de racemização de ácido (s)-3-carbamoilmetil-5-metil-hexanoico